1.Advances in Immunotherapy for Malignant Pleural Mesothelioma.
Yujia CHI ; Yiliang LIU ; Jun ZHAO
Chinese Journal of Lung Cancer 2022;25(4):259-265
Patients with malignant pleural mesothelioma (MPM) usually present with poor prognosis and short survival period, and there has been a lack of effective treatment options for a long time. Chemotherapy has limited improvement in the clinical outcome of advanced patients (the median survival is less than one year), and it is difficult to find suitable targets for targeted therapy. Recent in-depth research on immunotherapy has changed the treatment pattern of MPM. Especially, the dual immunotherapy regimen significantly improved the survival outcome of patients across subgroups and prolonged the survival time of MPM patients. Therefore, it has been approved for unresectable MPM as first-line treatment for patients. The exploration of other mono or combo immunotherapy regimens in the first and second-line settings of MPM is also underway. How to identify the best beneficial population of each regimen through predictive biomarkers is also a hot spot for researchers. This article will focus on the most up-to-date progress of MPM epidemiology, histological characteristics, pathogenesis, treatment patterns and the advances of immunotherapy in the disease.
.
Combined Modality Therapy
;
Humans
;
Immunotherapy
;
Lung Neoplasms/drug therapy*
;
Mesothelioma/drug therapy*
;
Mesothelioma, Malignant
;
Pleural Neoplasms/drug therapy*
2.Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2019;22(2):118-124
Lung cancer is the most commonly diagnosed cancer worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer seriously affect the patients' quality of life and prognosis. The management of MPE includes thoracentesis, pleurodesis, indwelling pleural catheters and drug perfusion in pleural cavity. Vascular endothelial growth factor (VEGF) and its receptor are a group of important ligands and receptors that affect angiogenesis. They are the main factors controlling angiogenesis, and they play an important role in the formation of MPE. Bevacizumab is a recombinant humanized VEGF monoclonal antibody, competitively binding to endogenous VEGF receptor. Bevacizumab can inhibit new blood vessel formation, reduce vascular permeability, prevent pleural effusion accumulation and slow the growth of cancers. This review aims to discuss the progress of bevacizumab in the treatment of MPE caused by non-small cell lung cancer (NSCLC), and explore the clinical application, efficacy, safety and future direction of bevacizumab.
.
Antineoplastic Agents
;
therapeutic use
;
Antineoplastic Agents, Immunological
;
therapeutic use
;
Carcinoma, Non-Small-Cell Lung
;
complications
;
pathology
;
Humans
;
Pleural Effusion, Malignant
;
drug therapy
;
Pleural Neoplasms
;
drug therapy
;
secondary
3.Intrapleural Perfusion Hyperthermic-Chemotherapy for Pleural Seeding of Lung Cancer.
Sang Hoon JHEON ; Hyung Seok KANG ; Sub LEE ; Oh Choon KWON ; Wook Su AHN ; Eung Bae LEE
The Korean Journal of Thoracic and Cardiovascular Surgery 2002;35(8):608-610
Lung cancer with pleural seeding has poor prognosis and is generally treated by intravenous anticancer chemotherapy only. We performed intrapleural perfusion hyperthermic-chemotherapy in two lung cancer patients with pleural seeding. Herein, we report our outcome with literature review.
Drug Therapy
;
Humans
;
Hyperthermia, Induced
;
Lung Neoplasms*
;
Lung*
;
Neoplasm Seeding
;
Perfusion*
;
Pleural Effusion
;
Pleurodesis
;
Prognosis
4.A case of malignant peritoneal mesothelioma.
Fang ZHAO ; Ying Liang ZHANG ; Xi LIU ; Ting Hao CHEN ; Jing LI
Chinese Journal of Industrial Hygiene and Occupational Diseases 2023;41(4):307-309
Malignant mesothelioma is a highly malignant disease that most often occurs in the pleural cavity, followed by the peritoneum and pericardium. Malignant peritoneal mesothelioma (MPM) accounts for 10%-15% of all mesothelioma. The most important risk factor for MPM is exposure to asbestos. MPM has no specific clinical symptoms, imaging and histopathology are critical for the diagnosis. There are currently no generally accepted guidelines for curative treatment of MPM. The patient mainly presented with abdominal pain, abdominal distension and discomfort. Due to extensive omentum metastasis, no further surgical treatment was performed. Pemetrexed combined with cisplatin chemotherapy was given for 2 cycles, and the patient is still alive.
Humans
;
Mesothelioma, Malignant/drug therapy*
;
Mesothelioma/diagnosis*
;
Pemetrexed/therapeutic use*
;
Cisplatin/therapeutic use*
;
Peritoneal Neoplasms/diagnosis*
;
Pleural Neoplasms
;
Lung Neoplasms/drug therapy*
5.Intrapleural chemotherapy with cisplatin and cytarabine in the management of malignant pleural effusion.
Tae Kyu LEE ; Jong Tae BAEK ; Suk Kyung LEE ; Sun Woo KIM ; Kee Won KIM ; Ji Won SUHR ; Suk Young PARK ; Kyung Shick LEE
Korean Journal of Medicine 1999;57(2):191-196
BACKGROUND: Maligant pleural effusions are common and significant problems in patient with advanced malignancies. In comparison with traditional sclerosing agent, intrapleural chemotherapy has a potential advantage of treating the underlying malignancy in addition to providing local control of th effusion. This study evaluated efficacy of intrapleural chemotherapy with cisplatin and cytarabine in the management of malignant pleural effusion from lung cancer and others. METHODS: 29 patients with pathology-proven malignant pleural effusion were prospectively analyzed to estimate the effect of intrapleural chemotherapy. A single dose of cisplatin 100mg/m plus cytarabine 1200mg/m in the 250ml normal saline were instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicity and response at 24hours, 1st, 2nd, 3rd week, and monthly interval. No recurrence of the effusion was considered a complete response(CR). Partial responses (PR) was defined as a 75% or greater decrease in the amount of effusion on serial chest radiographs. RESULTS: The overall response rate(CR plus PR) was 93.1% (27 of 29 patients). The median length of response was 7.5 months. Among 17 patients who were assessable until they died, 14 patients(82%) maintained complete response at the last follow-up. One patient experienced reversible grade 4 myelosuppression, 3 patients had grade 3 nausea & vomiting. 2 patients had empyema, and 2 patients had wound infection. CONCLUSIONS: The outcome of this trial indicated that the intrapleural chemotherapy with cisplatin and cytarabine with little treatment related mortality and morbidity.
Chest Tubes
;
Cisplatin*
;
Cytarabine*
;
Drug Therapy*
;
Empyema
;
Follow-Up Studies
;
Humans
;
Lung Neoplasms
;
Mortality
;
Nausea
;
Pleural Effusion
;
Pleural Effusion, Malignant*
;
Prospective Studies
;
Radiography, Thoracic
;
Recurrence
;
Vomiting
;
Wound Infection
6.Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion.
Kee Won KIM ; Suk Young PARK ; Myung Sook KIM ; Seok Chan KIM ; Eun Hee LEE ; So Young SHIN ; Jong Ho LEE ; Jong Bum KWEON ; Kuhn PARK
Cancer Research and Treatment 2004;36(1):68-71
PURPOSE: The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m2 plus cytarabine 1200 mg/m2 in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE. RESULTS: The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable. CONCLUSION: The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.
Chest Tubes
;
Cisplatin*
;
Cytarabine*
;
Drainage
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Lung Neoplasms
;
Pleural Effusion
;
Pleural Effusion, Malignant*
;
Prospective Studies
;
Recurrence
7.Fibrinolysis of loculated pleural effusion in malignant mesothelioma.
Singapore medical journal 2005;46(3):148-reply 148
8.Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma.
Xiaomei ZENG ; Zhaoyou JIANG ; Jianchun DUAN
Chinese Journal of Lung Cancer 2022;25(1):7-13
BACKGROUND:
Malignant pleural mesothelioma (MPM) is a highly aggressive disease arising from pleural mesothelial cells. Advanced pleural mesothelioma has a poor prognosis, with a median survival of no more than 15 months. First line standard chemotherapy regimen recommended is Pemetrexed based chemotherapy regimen, with or without bevacizumab. There is no consensus on whether patients who have received first-line standard chemotherapy can benefit from pemetrexed maintenance chemotherapy. The study aimed to investigate the efficacy and safety of pemetrexed maintenance therapy (PMT) after treatment with a pemetrexed and platinum regimen for patients with MPM.
METHODS:
A total of 40 MPM patients were collected from Cancer Hospital Chinese Academy of Medical Sciences from January 2013 to January 2018, eligible patients were unresectable MPM, without disease progression following 4 to 6 cycles of pemetrexed and platinum, including pemetrexed maintenance therapy group (22 cases) and observation group (18 cases). The last follow-up was conducted in January 2020. The primary endpoint were progression free survival (PFS), and the secondary end points were overall survival (OS), the efficacy, adverse reactions of PMT.
RESULTS:
The median PFS in the PMT arm was longer than that in the observation arm (8.5 mon vs 3 mon, P=0.008), but there was no significant difference in median OS (26.4 mon vs 15.7 mon, P=0.177). Objective response rate (ORR) of two group were 22.7% and 0%, respectively. The grade 3-4 toxicity in PMT group included grade 4 neutropenia in 1 patient (4.5%), grade 3 neutropenia in 1 patient (4.5%), grade 4 anemia in 1 patient (4.5%) and grade 3 nausea and anorexia in 1 patient (4.5%).
CONCLUSIONS
Pemetrexed maintenance therapy following initial pemetrexed and platinum chemotherapy improve PFS in patients with MPM, and is well tolerated.
Antineoplastic Combined Chemotherapy Protocols/adverse effects*
;
Cisplatin/therapeutic use*
;
Humans
;
Lung Neoplasms/drug therapy*
;
Mesothelioma/drug therapy*
;
Mesothelioma, Malignant
;
Neutropenia
;
Pemetrexed/therapeutic use*
;
Platinum/therapeutic use*
;
Pleural Neoplasms/drug therapy*
9.Multimodal Treatment of Pleuropulmonary Blastoma: Two case report.
Joonseok PARK ; Joungho HAN ; Honghoe KOO ; Jhingook KIM
The Korean Journal of Thoracic and Cardiovascular Surgery 2003;36(8):614-618
Pleuropulmonary blastoma (PPB) is a rare intrathoracic neoplasm, found solely in childhood. The usual symptoms are dyspnea, chest discomfort, recurrent respiratory infections, fever, dry cough, and chest pain. The progress of PPB is usually aggressive and its progress is generally poor. Lymphatic spread to the hilar and mediastinal nodes can occur. Distant metastasis is found in brain, bones, and intra-abdominal organs. Surgical resection is the treatment of choice. When the disease is too extensive for surgical resection, neoadjuvant chemotherapy can be used. We report 2 cases of pleuropulmonary blastoma in children successfully treated with multimodal therapy.
Brain
;
Chest Pain
;
Child
;
Combined Modality Therapy*
;
Cough
;
Drug Therapy
;
Dyspnea
;
Fever
;
Humans
;
Neoplasm Metastasis
;
Pleural Neoplasms
;
Respiratory Tract Infections
;
Thorax
10.Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.
Hesham A El HOSSIENY ; Fatma ABOULKASEM ; M Abdel RAHMAN
Chinese Journal of Lung Cancer 2010;13(1):54-59
BACKGROUND AND OBJECTIVEThis retrospective study was designed to evaluate the response and survival of malignant pleural mesothelioma to radiotherapy when delivered with surgery and chemotherapy and when delivered alone or with chemotherapy.
METHODSA study for 110 patients with malignant pleural mesothelioma who presented to radiotherapy department, National Cancer Institute, Cairo and received radiation therapy in the period fromJanuary 1999 to July 2007.
RESULTSForty-six patients (41.8%) received trimodality therapy (surgery & adjuvant or neoadjuvant chemotherapy & adjuvant radiotherapy), while bimodality therapy (chemotherapy & radiotherapy) in 38 patients (34.5%), while 26 patients (23.6%) received single modality therapy (palliative radiotherapy), 22 patients (20%) developed local recurrence, 22 patients (20%) developed distant metastases months, 14 patients (12.7%) developed local disease progression, 25 patients (22.7%) are still alive and free of disease at time of reporting. The median survival for all patients was 16 months, while 12 and 18 months overall survival were 63.6% & 31.8% respectively while median survival for stage II, III, IV patients was 16.5, 12.5 and 8 months respectively.
CONCLUSIONMultimodality approach involving surgery, chemotherapy and radiotherapy have been evaluated and proved its superiority in improving survival, especially in stages II.
Adult ; Aged ; Chemotherapy, Adjuvant ; methods ; Combined Modality Therapy ; methods ; Female ; Humans ; Male ; Mesothelioma ; drug therapy ; mortality ; radiotherapy ; Middle Aged ; Neoadjuvant Therapy ; methods ; Pleural Neoplasms ; drug therapy ; mortality ; radiotherapy ; Radiotherapy, Adjuvant ; methods ; Retrospective Studies ; Survival Rate